ACTEMRA® (tocilizumab) is an interleukin-6 (IL-6) receptor antagonist indicated for the treatment of rheumatoid arthritis (RA), giant cell arthritis (GCA), systemic sclerosis-associated interstitial lung disease (SSc-ILD), polyarticular juvenile idiopathic arthritis (PJIA), and systemic juvenile idiopathic arthritis (SJIA), and cytokine release syndrome (CRS). This medication is available as an infusion or a subcutaneous injection.

AMVUTTRA® (vutrisiran) is a small interfering RNA (siRNA) therapeutic indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) in adults. This medication targets the transthyretin (TTR) gene to reduce the production of abnormal TTR protein, which can accumulate in tissues and cause damage in patients with hATTR. AMVUTTRA is administered as a subcutaneous injection once every three months, offering a long-acting treatment option for managing this progressive condition.

AVSOLA® (infliximab-axxq) is a TNF-alpha inhibitor indicated for the treatment of rheumatoid arthritis (RA), crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis

BENLYSTA® (belimumab) is a B-lymphocyte stimulator (BLyS) inhibitor indicated for the treatment of systemic lupus erythematosus (SLE) in autoantibody-positive adult patients, and active lupus nephritis

BRUIMVI® (brucemizumab) is a monoclonal antibody therapeutic indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults. This medication targets the CD20 protein on the surface of B-cells, a type of immune cell that plays a role in the autoimmune process underlying MS. By depleting these B-cells, BRUIMVI helps to reduce inflammation and prevent the progression of disability associated with MS. BRUIMVI is administered as an intravenous infusion, typically given every 6 months after an initial loading phase, offering a long-acting treatment option for managing this chronic neuroinflammatory disease.

CIMZIA® (certolizumab pegol) is a TNF-alpha inhibitor indicated for the treatment of rheumatoid arthritis (RA), Crohn's disease, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis

COSENTYX® (secukinumab) is a monoclonal antibody therapeutic indicated for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis in adults. This medication selectively targets interleukin-17A (IL-17A), a key cytokine that drives inflammation in multiple autoimmune conditions. By blocking IL-17A, COSENTYX helps reduce inflammation, joint damage, and skin symptoms associated with these conditions. COSENTYX is administered as a subcutaneous injection, with an initial loading phase followed by monthly maintenance dosing, offering a versatile treatment option for managing multiple chronic inflammatory diseases.

ENTYVIO® (vedolizumab) is an integrin receptor antagonist indicated for the treatment of moderately to severely active ulcerative colitis and moderately to severely active Crohn's disease

EVENITY® (romosozumab-aqqg) is a sclerostin inhibitor indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture

FASENRA® (benralizumab) is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older with an eosinophilic phenotype and eosinophillic granulomatosis with polyangiitis (EGPA)